291 related articles for article (PubMed ID: 24002588)
1. CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia.
Mandoli A; Singh AA; Jansen PW; Wierenga AT; Riahi H; Franci G; Prange K; Saeed S; Vellenga E; Vermeulen M; Stunnenberg HG; Martens JH
Leukemia; 2014 Apr; 28(4):770-8. PubMed ID: 24002588
[TBL] [Abstract][Full Text] [Related]
2. Runx1 is required for hematopoietic defects and leukemogenesis in Cbfb-MYH11 knock-in mice.
Hyde RK; Zhao L; Alemu L; Liu PP
Leukemia; 2015 Aug; 29(8):1771-8. PubMed ID: 25742748
[TBL] [Abstract][Full Text] [Related]
3. HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia.
Richter LE; Wang Y; Becker ME; Coburn RA; Williams JT; Amador C; Hyde RK
Mol Cancer Res; 2019 Jun; 17(6):1241-1252. PubMed ID: 30814129
[TBL] [Abstract][Full Text] [Related]
4. RUNX1 and CBFβ-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development.
Zhen T; Cao Y; Ren G; Zhao L; Hyde RK; Lopez G; Feng D; Alemu L; Zhao K; Liu PP
Blood; 2020 Nov; 136(21):2373-2385. PubMed ID: 32929473
[TBL] [Abstract][Full Text] [Related]
5. Gata2 deficiency delays leukemogenesis while contributing to aggressive leukemia phenotype in Cbfb-MYH11 knockin mice.
Saida S; Zhen T; Kim E; Yu K; Lopez G; McReynolds LJ; Liu PP
Leukemia; 2020 Mar; 34(3):759-770. PubMed ID: 31624376
[TBL] [Abstract][Full Text] [Related]
6. Role of Cbfb in hematopoiesis and perturbations resulting from expression of the leukemogenic fusion gene Cbfb-MYH11.
Kundu M; Chen A; Anderson S; Kirby M; Xu L; Castilla LH; Bodine D; Liu PP
Blood; 2002 Oct; 100(7):2449-56. PubMed ID: 12239155
[TBL] [Abstract][Full Text] [Related]
7. Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia.
Diffner E; Beck D; Gudgin E; Thoms JA; Knezevic K; Pridans C; Foster S; Goode D; Lim WK; Boelen L; Metzeler KH; Micklem G; Bohlander SK; Buske C; Burnett A; Ottersbach K; Vassiliou GS; Olivier J; Wong JW; Göttgens B; Huntly BJ; Pimanda JE
Blood; 2013 Mar; 121(12):2289-300. PubMed ID: 23327922
[TBL] [Abstract][Full Text] [Related]
8. Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia.
Engel ME; Hiebert SW
Cancer Treat Res; 2010; 145():127-47. PubMed ID: 20306249
[TBL] [Abstract][Full Text] [Related]
9. Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFβ/MYH11 gene expression.
Xiaosu Z; Leqing C; Yazhen Q; Yu W; Xiaohui Z; Lanping X; Xiaojun H; Yingjun C
Ann Hematol; 2019 Jan; 98(1):73-81. PubMed ID: 30159599
[TBL] [Abstract][Full Text] [Related]
10. Cbfb/Runx1 repression-independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11.
Hyde RK; Kamikubo Y; Anderson S; Kirby M; Alemu L; Zhao L; Liu PP
Blood; 2010 Feb; 115(7):1433-43. PubMed ID: 20007544
[TBL] [Abstract][Full Text] [Related]
11. CBFβ-MYH11 interferes with megakaryocyte differentiation via modulating a gene program that includes GATA2 and KLF1.
Yi G; Mandoli A; Jussen L; Tijchon E; van Bergen MGJM; Cordonnier G; Hansen M; Kim B; Nguyen LN; Jansen PWTC; Vermeulen M; van der Reijden B; van den Akker E; Bond J; Martens JHA
Blood Cancer J; 2019 Mar; 9(3):33. PubMed ID: 30850577
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/CBFB::MYH11.
Gao J; Santana-Santos L; Fu L; Alvey E; Chen Q; Wolniak K; Xia Z; Aqil B; Behdad A; Ji P; Sukhanova M; Abaza Y; Altman JK; Chen YH; Lu X
Eur J Haematol; 2024 Jun; 112(6):964-974. PubMed ID: 38388794
[TBL] [Abstract][Full Text] [Related]
13. Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia.
Richter L; Wang Y; Hyde RK
Oncotarget; 2016 Oct; 7(40):66255-66266. PubMed ID: 27542261
[TBL] [Abstract][Full Text] [Related]
14. Molecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia.
Castilla LH; Bushweller JH
Adv Exp Med Biol; 2017; 962():229-244. PubMed ID: 28299661
[TBL] [Abstract][Full Text] [Related]
15. Rare type I CBFβ/MYH11 fusion transcript in primary acute myeloid leukemia with inv(16)(p13.1q22): a case report.
Zhang W; Wang H; Zhang P; Li H; Ma X; Liu H
Braz J Med Biol Res; 2021; 54(12):e11605. PubMed ID: 34730684
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.
Heibert SW; Lutterbach B; Durst K; Wang L; Linggi B; Wu S; Wood L; Amann J; King D; Hou Y
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S31-4. PubMed ID: 11587363
[TBL] [Abstract][Full Text] [Related]
17. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
[TBL] [Abstract][Full Text] [Related]
18. CBFβ-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia.
Pulikkan JA; Hegde M; Ahmad HM; Belaghzal H; Illendula A; Yu J; O'Hagan K; Ou J; Muller-Tidow C; Wolfe SA; Zhu LJ; Dekker J; Bushweller JH; Castilla LH
Cell; 2018 Jun; 174(1):172-186.e21. PubMed ID: 29958106
[TBL] [Abstract][Full Text] [Related]
19. The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain.
Durst KL; Lutterbach B; Kummalue T; Friedman AD; Hiebert SW
Mol Cell Biol; 2003 Jan; 23(2):607-19. PubMed ID: 12509458
[TBL] [Abstract][Full Text] [Related]
20. Core-binding factor beta (CBFbeta), but not CBFbeta-smooth muscle myosin heavy chain, rescues definitive hematopoiesis in CBFbeta-deficient embryonic stem cells.
Miller JD; Stacy T; Liu PP; Speck NA
Blood; 2001 Apr; 97(8):2248-56. PubMed ID: 11290585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
